Common use of Publications and Presentations Clause in Contracts

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication (a) Corvus may publish or dissemination of present the final results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC Study (in accordance with this Section 2.1. Each Party shall provide to the JSC the 8.2); provided that Corvus gives Genentech an opportunity to review and provide comments in accordance with subsection (b). (b) In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the submitting “Reviewing Party’s ”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts or presentations (including information to be presented verballyand written descriptions of oral presentations) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation (or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period], not in the case of abstracts) prior to submit such abstract or manuscript the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to make such presentation until the other Publishing Party is given up to as soon as reasonably possible, but in any case within [***] (or [**] days from *], in the date case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such written Study Data or Sample Data, but shall give reasonable consideration to any request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSCReviewing Party; provided, however, at the request of the Reviewing Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Publishing Party also shall have the right to require that its Confidential Information that is disclosed in any (i) delete from such proposed publication or presentation be deleted prior Confidential Information of the Reviewing Party (including Sample Data), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for [***], to permit the Reviewing Party to prepare and file a patent application. In The Publishing Party shall comply with all applicable requirements regarding disclosure of industry support (financial or otherwise) in connection with any permitted publication publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentation presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, the other including with respect to results from such Party’s contribution shall be duly recognized, and co-authorship development activities outside of the Study. (c) Authorship of publications or presentations of final results of the Study and/or any Study Data or Sample Data shall be determined in accordance with customary industry standardsappropriate scientific and academic standards and customs.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1[********]. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Program [********] at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [********] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. Further, AstraZeneca shall [********]. Once such abstractsan abstract, manuscripts manuscript or presentations have presentation has been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, approved by the JSCa Party [********], the same abstractsabstract, manuscripts manuscript or presentations do presentation does not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication Syndax shall publish or dissemination of present the final results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC Study (in accordance with this Section 2.1. Each Party shall provide 8.2), whether such results are positive or negative in any respect, such as with respect to the JSC the opportunity to review any Combination or either Compound. Authorship of the submitting Party’s proposed abstracts, manuscripts publications or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate any Study Data or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship Sample Data shall be determined in accordance with customary appropriate scientific and academic standards and customs. In the event that either Party (for purposes of this Section, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least *** (or ***, in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within *** (or ***, in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any request by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data owned solely or jointly by the Reviewing Party), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for ***, to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry standardssupport (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study.

Publications and Presentations. The Parties acknowledge that scientific publications must Jazz and its Affiliates may publish or present, or permit to be strictly monitored to prevent published or presented, the design (including clinical design, but excluding any adverse effect from premature publication Codiak Platform Know-How) or dissemination of results of the activities hereunderDevelopment, Manufacture, Commercialization, or other Exploitation of the Collaboration Targets, Licensed Compounds, or Licensed Products (the “Covered Results”). Except Codiak agrees that, except as required by Applicable Laws, each Party agrees that it and its Affiliates shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Covered Results without the prior review by and the approval of Jazz, which approval shall not be unreasonably withheld, conditioned or delayed; provided, that it shall be deemed reasonable for Jazz to withhold its consent to any request by Codiak to publish or present any Covered Results prior to the JSC in accordance with Section 2.1planned publication or dissemination of such Covered Results by Jazz or its Affiliates. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts(a) abstracts and manuscripts for scientific journals or conferences that relate to the Covered Results at least [***] prior to intended submission for publication, manuscripts or and (b) presentations at scientific conferences (including information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon presentation. Upon written request from the TSC a Party given within such [*****] day applicable review period, the other Party shall (i) not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for applications are filed to protect any material unpatented Know-How disclosed in such publication or presentation which the JSC that such Party reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to may be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its patentable and (ii) remove any Confidential Information of such Party that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. Once such abstracts, manuscripts or presentations (or the information contained therein) have been reviewed and, if applicable, modified for publication or presentation pursuant to this Section 9.4, the same abstracts, manuscripts or presentations (and the information contained therein) do not have to be provided again by one Party to the other Party for review for a later submission for publication. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific lead-time is a key element of the value of the Research Activities under the Research Program and further agree that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities Research Activities hereunder. Except as required by Applicable LawsAccordingly, each neither Party agrees that it shall not publish publish, present or present, or permit otherwise disclose any material related to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each The publishing Party shall provide to the JSC other Party the opportunity to review any each of the submitting publishing Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate that contain the non-publishing Party’s Confidential Information or disclose any unpatented Information related to the results of the Research Program, the Development of a Candidate or the Commercialization of a Product Program at least [*****] days prior to its intended presentation or submission for publication, and such submitting the publishing Party agrees, upon written request from the TSC non-publishing Party given within such [*****] day thirty (30)-day period, not to submit such abstract or manuscript for publication or to make such presentation until the other non-publishing Party is given up to [*****] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any material unpatented Information disclosed in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once Notwithstanding the foregoing, in no event shall a Party have the right, in reliance on this Section 7.6, to publish, present or otherwise disclose any Confidential Information of the other Party without such abstracts, manuscripts or presentations have been reviewed by other Party’s prior written consent; provided that the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also Company shall have the right to require that its Confidential publish, present or otherwise disclose the Research Program Information that is disclosed in with respect to any such proposed publication Acquired Compound or presentation be deleted Acquired Product without the prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognizedwritten consent of SpinCo, and co-authorship SpinCo shall be determined in accordance have the right to publish, present or otherwise disclose the Research Program Information with customary industry standardsrespect to any SpinCo Selected Compound or any Declined Compound without the prior written consent of the Company.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Program or any Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Program or any Development of a Candidate or the Commercialization of a Product Program at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party (i) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings and (ii) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program to the Development of a Candidate or the Commercialization of a Product, including, but not limited extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Novartis to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the publication or dissemination of such Covered Results by Novartis. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Program at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] ]day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same subject matter disclosed in such abstracts, manuscripts Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company's application requesting confidential treatment under Rule 406 of the Securities Act. or presentations do does not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Subject to the foregoing obligations of this Section 6.3, TAKEDA may use the results of the Research Program for the purpose and to the extent necessary to develop and commercialise Products in accordance with this Agreement. Notwithstanding the foregoing, TAKEDA shall exclusively control all scientific publications and presentations that contain any data relating to an Optimized Lead Compound or Product. ARCHEMIX agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, any data arising out of the Development Program relating to an Optimized Lead Compound or Product without the prior review and express written approval of TAKEDA which may be withheld at TAKEDA’s sole discretion.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Program or any Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Program or any Development of a Candidate or the Commercialization of a Product Program at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party (i) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings and (ii) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific lead-time is a key element of the value of the research and development activities under the Collaboration and further agree that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination disclosure of results of the research or development activities hereunder. Except At least thirty (30) days prior to submission of any material related to the research or development activities hereunder for publication or presentation, the submitting Party will provide to the receiving Party a draft of such material for its review and comment. The receiving Party will provide any comments to the submitting Party within twenty (20) days of receipt of such materials alerting the submitting Party to the presence of the receiving Party’s Confidential Information or patentable subject matter that requires protection and in each case, specifically identifying such information (“Notice of Objection”). Each Party will reasonably review proposed publications and presentations submitted by the other Party as promptly as possible and will not unreasonably withhold its consent to such publications or presentations that have been submitted for review with less than the required by Applicable Lawsnotice period. 5.3.1 In the event the receiving party makes such Notice of Objection, each Party agrees that it the submitting party shall refrain from disclosing the material until the receiving Party’s Confidential Information, as identified in the Notice of Objection, is removed. Once the receiving Party’s Confidential Information has been removed, the Notice of Objection will be deemed withdrawn and the submitting party shall not publish or presentbe restricted from publishing the material, or permit to be published or presented, provided that any objection based on patentable subject matter contained in the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC material has also been addressed in accordance with Section 2.1the terms of section 5.3.2. 5.3.2 If the Notice of Objection identifies patentable subject matter then the submitting Party will withhold the material from submission for publication or presentation and the Parties shall work together in good faith and, as quickly as possible after receipt of the Notice of Objection, to file patents and take all necessary measures to establish and preserve proprietary rights that may be contained in the material being submitted for publication or presentation as identified in the Notice of Objection. Each Once the Parties have taken such steps to protect the patentable subject matter, the Notice of Objection will be deemed withdrawn and the submitting party shall not be restricted from publishing the material. In no event, provided the submitting Party is acting in good faith to protect the patentable material, shall provide a Notice of Objection relating to patentable material delay publication for longer than three (3) months from the JSC date the opportunity to review any Notice of Objection was received by the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, Program or the Development of a Candidate or the Commercialization of a Product Program at least [* (*****] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [* (*****] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (*****] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes may be patentable. In the event that the Parties disagree on a proposed publication or presentation, they will discuss the matter in good faith and the matter shall be decided in accordance with Section 2.1.5 as a Unanimous Decision, provided that if such Disputed Matter is patentablenot resolved by the Designated Senior Officers within * (*) days after the date the Designated Senior Officers first met to consider such Disputed Matter or * (*) days after the date the JEC first met to consider such Disputed Matter, whichever is later, then the Disputed Matter shall not be resolved in accordance with Section 13.1, but instead, ARQULE shall have the right to make the final decision on publication or presentation of the results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once such abstracts, manuscripts or presentations have been reviewed published or presented by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation; provided, that, ARQULE shall be permitted to use data generated by ARQULE and information about the Target in any such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings. 12. Notwithstanding anything to the contrary in the Agreement, this Amendment or any Annual Research Plan, ARQULE shall perform the *studies for the DS Target * and DS shall bear all costs associated with such * studies, including, but not limited to, *, as requested by DS and agreed by ARQULE. A plan for the * studies for the DS Target *, including the costs, shall be agreed upon by the Parties. Any amendment, modification and/or update to such plan shall be discussed and agreed by the Parties. ARQULE shall invoice DS (a) quarterly in advance, at least * (*) days prior to each Calendar Quarter, for all ARQULE FTEs involved in performing or managing external performance of such * studies and (b) quarterly in arrears for all Third Party Costs associated with such * studies, including without limitation, * costs. DS shall pay such invoices for ARQULE FTEs at least * (*) days before the first day of each Calendar Quarter and shall pay such invoices for Third Party Costs within * (*) days after receipt thereof. 13. The Parties agree to issue a press release relating to this Amendment in the form attached hereto as Exhibit 1 within seven (7) days after the Effective Date. 14. In all other respects, the Agreement shall remain in full force and effect and shall not be modified hereby. This Amendment may be executed as of the date first written above in any number of counterparts, each of which shall be an original, but all of which together shall constitute one and the same agreement. ArQule, Inc. By: /s/ Xxxxx Xxxxx Name: Xxxxx Xxxxx Title: Chief Executive Officer Daiichi Sankyo Co., Ltd. By: /s/Xxxxxxxx Xxxxxxxx Name: Xxxxxxxx Xxxxxxxx Title: Senior Executive Officer and Head of R&D Division * Contact: Toshiaki Sai Corporate Office, Corporate Communications Daiichi Sankyo Co., Ltd. (Japan) +00-0-0000-0000 Xxxxxxx X. Xxxx VP, Investor Relations/ Corp. Communications ArQule, Inc. (000) 000-0000 Woburn, MA, October 12, 2010 — ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, and it includes a two-year extension based on the application of the proprietary ArQule Kinase Inhibitor Platform (AKIP™) technology. “This technology has provided us with a unique and innovative approach for discovery in the treatment of cancer,” said Xx. Xxxxxxxx Xxxxxxxx, the Global Head of Research, Daiichi Sankyo. “We expect that the expansion of this collaboration will produce other drug candidates and lay the foundation for future growth in this field.” Consistent with the existing AKIP™ collaboration, the economic terms provided for in the expanded agreement include payments for research support, licensing fees for compounds discovered as a result of this research, milestone payments related to clinical development, regulatory review and sales, and tiered royalty payments on net sales of each product. Daiichi Sankyo will have an option to license compounds directed to the targets defined under the agreement following the completion of certain pre-clinical studies. ArQule retains the option to co-commercialize any resulting licensed products in the U.S. “Our initial drug discovery collaboration has identified a development candidate for one target, and we are optimizing advanced lead compounds for the other target,” said Xx. Xxxxxx X.X. Xxxx, chief scientific officer of ArQule. “The expansion of this collaboration will continue to deploy AKIP technology to discover novel kinase inhibitors for additional oncology targets over the next two years.” Kinases play pivotal roles in modulating diverse cellular activities and have been implicated as important mediators of certain forms of cancer and other diseases. The AKIP™ technology is based on a novel binding mode that leads to inhibition of target kinases by small molecules that do not compete with adenosine triphosphate (ATP). ArQule has identified binding sites in more than 200 kinases involved in multiple therapeutic areas that are amenable to such non-ATP competitive inhibition. ArQule’s ability to rationally design novel kinase inhibitors that encompass new chemical spaces allows for an expanding intellectual property estate. The Company believes that non-ATP competitive small molecule inhibitors may have fewer off-target side effects and utility in a broad range of human diseases. ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and upcoming Phase 3 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company’s pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable LawsLaw, each Party agrees that it shall will not publish or present, or permit to be published or presented, the results of the Research ProgramDevelopment Program to the extent such results refer to or derive from the Xxxxxxxx IP, the Development of a Candidate Millennium Technology IP or the Commercialization of a Product, including, but not limited to, studies Other IP or clinical trials carried out by such Party as part otherwise constitute Confidential Information of the Collaboration, other Party (the “Covered Results”) without the prior review by and the written approval of the JSC in accordance with Section 2.1. Each Party shall provide other Party, which approval will not be unreasonably withheld, conditioned or delayed; provided, that it will not be deemed unreasonable for Millennium to withhold its consent to any request by Xxxxxxxx to publish or present any Covered Results relating to the JSC Selected Molecules or Designated ARC Molecules. Subject to the foregoing, each Party will provide the other Party with the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any material unpatented technology disclosed in such publication or presentation which the JSC that it reasonably believes is may be patentable. The publishing Party will take into account the reasonable comments or changes proposed by the other Party on any publication or presentation. Once such abstracts, manuscripts or presentations have been reviewed and, where applicable, approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall will have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall will be duly recognized, and co-authorship shall will be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, Program or the Development of a Candidate or the Commercialization of a Product Program at least [* (*****] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [* (*****] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (*****] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes may be patentable. In the event that the Parties disagree on a proposed publication or presentation, they will discuss the matter in good faith and the matter shall be decided in accordance with Section 2.1.5 as a Unanimous Decision, provided that if such Disputed Matter is patentablenot resolved by the Designated Senior Officers within * (*) days after the date the Designated Senior Officers first met to consider such Disputed Matter or * (*) days after the date the JEC first met to consider such Disputed Matter, whichever is later, then the Disputed Matter shall not be resolved in accordance with Section 13.1, but instead, ARQULE shall have the right to make the final decision on publication or presentation of the results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once such abstracts, manuscripts or presentations have been reviewed published or presented by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation; provided, that, ARQULE shall be permitted to use data generated by ARQULE and information about the Target in any such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings. 12. Notwithstanding anything to the contrary in the Agreement, this Amendment or any Annual Research Plan, ARQULE shall perform the *studies for the DS Target * and DS shall bear all costs associated with such * studies, including, but not limited to, *, as requested by DS and agreed by ARQULE. A plan for the * studies for the DS Target *, including the costs, shall be agreed upon by the Parties. Any amendment, modification and/or update to such plan shall be discussed and agreed by the Parties. ARQULE shall invoice DS (a) quarterly in advance, at least * (*) days prior to each Calendar Quarter, for all ARQULE FTEs involved in performing or managing external performance of such * studies and (b) quarterly in arrears for all Third Party Costs associated with such * studies, including without limitation, * costs. DS shall pay such invoices for ARQULE FTEs at least * (*) days before the first day of each Calendar Quarter and shall pay such invoices for Third Party Costs within * (*) days after receipt thereof. 13. The Parties agree to issue a press release relating to this Amendment in the form attached hereto as Exhibit 1 within seven (7) days after the Effective Date. 14. In all other respects, the Agreement shall remain in full force and effect and shall not be modified hereby.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program to the Development of a Candidate or the Commercialization of a Product, including, but not limited extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Novartis to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the publication or dissemination of such Covered Results by Novartis. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the written approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Program at least [* (*****] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [* (*****] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (*****] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. Notwithstanding the foregoing, in the event that a Party reasonably requests a response by the other Party in less than * (*) days, then the reviewing Party shall use Commercially Reasonable Efforts to respond in the time period requested. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings and (b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunderhereunder or prepublication of patentable data and content. It is agreed that both Parties may issue press releases only pursuant to Section 7.2. As long as ImmunoGen has not exercised a Co-Development Option to a Licensed Product, Biotest shall be entitled to publish details, data and/or results on the Research Program or the Development Program, e.g., in scientific articles or oral presentations, pursuant to this Section 7.3. Provided that ImmunoGen has exercised a Co-Development Option to a Licensed Product both Parties shall be entitled to publish in full range on the respective Licensed Product only pursuant to this Section 7.3. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Licensed Product, including, including but not limited to, studies or clinical trials carried out by such Party as part of the CollaborationCollaboration under this Agreement, without the prior review by and the approval of of, the JSC in accordance JDC, with Section 2.1respect to Development activities or, provided that ImmunoGen has exercised a Co-Development Option and a JMC has been established, the JMC, with respect to Commercialization activities. Each Party shall provide to the JSC JDC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, Program or the Development of a Candidate or the Commercialization of a Licensed Product at least [***] ([**] *]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC JDC within such [***] ([**] *]) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([**] *]) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC JDC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSCJDC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC JDC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Notwithstanding anything to the contrary contained herein, the right to publish or present, or permit to be published or presented, the results of the Research Program shall be governed by the terms of the Collaborative Research Agreement. Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Program at least [* (*****] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [* (*****] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (*****] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. In the event that the Parties disagree on a proposed publication or presentation, they will discuss the matter in good faith and ARQULE shall have the right to make the final decision on publication or presentation of the results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once such abstracts, manuscripts or presentations have been reviewed published or presented by the JSCeach Party in accordance with this Section 5.3, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation, provided that ARQULE shall be permitted to use data generated by ARQULE and information about AKT in any such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies Licensed Product to the extent such results refer to or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [***] ([**] *]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([**] *]) days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies Licensed Product to the extent such results refer to or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, research conducted by sanofi-aventis under or pursuant to this Agreement to the Development of a Candidate extent such results refer to or otherwise relate to the Commercialization of a Product, including, but not limited to, studies Licensed Technology or clinical trials carried out by such Party as part of Licensed Patent Rights (the Collaboration, “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [***] ([**] *]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [***]-[***] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([**] *]) days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge Each of Amgen and KKC shall be free to: 12.6.1 present findings with respect to the Product at symposia and other meetings of healthcare professionals, and congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”); provided, however, unless otherwise agreed by the Parties, that scientific publications must be strictly monitored (i) the Party presenting at any such Scientific Meeting shall have complied with the provisions of this Section 12.6 and Section 12.7 (Scientific Papers, Abstracts and Posters) with respect to prevent such presentation, and, with respect to any adverse effect from premature publication or dissemination such Scientific Meeting at which a Party is presenting, such presenting Party shall inform the other Party of results of such Scientific Meeting and where invitation is required, invite the activities hereunder. Except as required by Applicable Laws, each other Party agrees that it to attend such Scientific Meeting; and (ii) a Party shall not publish organize or presentsponsor any satellite symposia in a country outside its territory without the other Party’s prior written consent, or permit not to be published unreasonably withheld; 12.6.2 publish in medical or presentedscientific journals (“Medical Journals”) articles and papers, including primary reports of clinical data, data obtained from Investigator Sponsored Studies, secondary or pooled analyses, and review papers concerning the results Product which have been prepared by or on behalf of such Party, for publication in the Research ProgramAmgen Territory or in the KKC Territory and related to studies conducted after the Effective Date outside or in the Territory concerning the Product (each a “Scientific Paper”); provided, however, that the Development Party proposing to publish such Scientific Paper shall have complied with the provisions of a Candidate or the Commercialization of a ProductSection 12.7 (Scientific Papers, including, but not limited to, studies or Abstracts and Posters) with respect to such Scientific Paper; and 12.6.3 disclose any clinical trials carried out data generated by such Party as part of concerning the CollaborationProduct in clinical trial registries; provided, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstractshowever, manuscripts or presentations (including information to be presented verbally) which relate to the Research Programthat, the Development of a Candidate or Party proposing to make such disclosure shall have provided the Commercialization of a Product other Party at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted Business Days prior to such publication or presentation. In any permitted publication or presentation disclosure (to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the comments made by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of In the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least event “[*****] days prior ]” wishes to its intended make a publication or public presentation or submission for publicationrelated to this Agreement, and such submitting Party agrees, upon written request from the TSC within such “[*****] day period]” shall deliver to Intec Pharma a copy of the proposed written publication or an outline of the proposed oral presentation at least thirty (30) days (or, not in the case of consulting or Third Party research agreements, such shorter period as required by the consulting or other research agreement) prior to submit such abstract or manuscript submission for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentablepresentation. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also Intec Pharma shall have the right to require that delay such proposed publication or presentation for up to sixty (60) days (or, in the case of consulting or Third Party research agreements, such shorter period as required by the consulting or other research agreement) in order to file patent applications protecting Intec Pharma’s rights in any information included in such proposed publication or presentation to the extent such filings are consistent with Section 7.1.1 (Intec Pharma Prosecution Rights), and Intec Pharma shall have the right to request the removal or redaction of any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such presentation. Intec Pharma shall not make any publication or presentation. In public presentation related to this Agreement or any permitted publication activities hereunder, except for such publications or presentation by a Partypublic presentations that (a) relate solely to the general applicability of the Accordion Pill System and (b) do not directly or indirectly identify “[***]”, the other Party’s contribution shall be duly recognizedProduct, and co-authorship shall be determined in accordance with customary industry standardsthe Agreement “[***]”Technology or any specific activities conducted under the Research Plan. NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored (a) Kite is committed to prevent timely publication of the final results following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study. Kite shall have the right to first publish or present any adverse effect from premature publication or dissemination of interim results and the final results of the activities hereunderStudy (in accordance with this Section 8.2); provided that Kite gives Humanigen an opportunity to review and provide comments in accordance with subsection (b), with such comments to be included at Kite’s sole discretion. Except as required Humanigen agrees not to publish any results of the Study or Sample Data (including any interim Study results or Sample Data) prior to the timely publication of such Study results by Applicable Laws, each Kite. (b) Each Party agrees that it shall not use reasonable efforts to publish or presentpresent scientific papers dealing with the Study in accordance with accepted scientific practice. The Parties agree that prior to submission of the Study results for publication or presentation or any other dissemination of results, or permit including oral presentations, the publishing Party shall invite the other to comment on the content of the material to be published or presentedpresented according to the following procedure: (i) At least forty-five (45) days prior to submission for publication of any paper, letter or any other publication, or thirty (30) days prior to submission for presentation of any abstract, poster, talk or any other presentation, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each publishing Party shall provide to the JSC other Party the opportunity to review any full details of the submitting Party’s proposed abstracts, manuscripts publication or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon in an electronic version. Upon written request from the TSC within such [*****] day periodother Party, the publishing Party agrees not to submit such abstract or manuscript data for publication or publication/presentation for an additional ninety (90) days in order to make such presentation until allow for actions to be taken to preserve rights for patent protection. (ii) The publishing Party shall give reasonable consideration to any request by the other Party is given up made within the periods set forth in subsection (i) above to [*****] days from modify the date of such written request publication and the Parties shall work in good faith and in a timely manner to seek appropriate patent protection for resolve any material in such publication or presentation which issue regarding the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission content for publication. Each . (iii) The publishing Party also shall have the right to require that its remove all Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, of the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standardsParty as requested by such other Party before finalizing the publication.

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees or consultants wishing to make a publication shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required by Applicable Laws, each Party agrees that it shall not publish the consulting or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by other agreement with such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verballyconsultant) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until presentation, (ii) the other reviewing Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that a delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship ownership shall be determined in accordance with customary industry standards. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (60) and ninety (90) day periods set forth in clauses (i) and (ii) above.

Publications and Presentations. The Parties acknowledge Amgen and Novartis shall be free to (provided that, with respect to Franchise Product 3, Novartis shall only have such rights after the Option Exercise Date): 11.6.1. present findings with respect to any Licensed Product at symposia and other meetings of healthcare professionals, and international, national or regional congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”); provided, however, unless otherwise agreed by the Parties, that scientific publications must be strictly monitored (i) the Party presenting at any such Scientific Meeting shall have complied with the provisions of Section 11.6 (Publications and Presentations) and Section 11.7 (Scientific Papers, Abstracts and Posters) with respect to prevent such presentation, and, with respect to any adverse effect from premature publication or dissemination such Scientific Meeting at which a Party is presenting, such presenting Party shall inform the other Party of results of such Scientific Meeting and where invitation is required, invite the activities hereunderother Party to attend such Amgen Ref. Except as required by Applicable Laws, each No. 2015641252 Page 52 Scientific Meeting; and (ii) a Party agrees that it shall not publish organize or presentsponsor any satellite symposia in a country outside its territory without the other Party’s prior written consent, or permit not to be published unreasonably withheld; 11.6.2. publish in medical and scientific journals and similar publications (“Medical Journals”) articles and papers, including primary reports of clinical data, secondary or presentedpooled analyses, and review papers concerning any Licensed Product which have been prepared by or on behalf of such Party, for publication outside or in the results Territory and related to studies conducted after the Effective Date outside or in the Territory concerning such Licensed Product (each a “Scientific Paper”); provided, however, that the Party proposing to publish such Scientific Paper shall have complied with the provisions of the Research ProgramSection 11.7 (Scientific Papers, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or Abstracts and Posters) with respect to such Scientific Paper; and 11.6.3. disclose any clinical trials carried out data generated by such Party as part of concerning any Licensed Product in clinical trial registries; provided, however, that the Collaboration, without Party proposing to make such disclosure shall have provided the prior review by and the approval of the JSC in accordance with Section 2.1. Each other Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted Business Days prior to such publication or presentation. In any permitted publication or presentation disclosure (to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the comments made by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that while scientific publications and presentations regarding results of Research, Development and Exploitation of Products by a Party is beneficial to both Parties, such scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable LawsLaw, each Party agrees that it shall will not publish or present, or permit to be published or presented, the results Confidential Information of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaborationother Party, without the prior review by and the written approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide Subject to the JSC foregoing, each Party will provide the other Party with the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product subject Confidential Information at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any material unpatented technology disclosed in such publication or presentation which the JSC that it reasonably believes is may be patentable. The publishing Party will take into account the reasonable comments or changes proposed by the other Party on any publication or presentation. Once such abstracts, manuscripts or presentations have been reviewed and, where applicable, approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall will have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall will be duly recognized, and co-authorship shall will be determined in accordance with customary industry standards. Notwithstanding the foregoing, during the Research Term, neither Party will publish nor present, nor permit to be published or presented, results of the Nonclinical Workplan, including the Product IP.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the research and Development activities hereunder. Except as required by Applicable LawsAccordingly, each during the Research Term neither Party agrees that it shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in such publications. For clarity, nothing in this Section 13.5 shall limit Dynavax’s right to publish or present, or permit to be published or presentedduring the Research Term, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, any studies or clinical trials carried out by such Party as part or on behalf of Dynavax prior to the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1Effective Date. Each Party shall agrees to provide to the JSC other Party the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verballyverbal presentations) which that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Research Program, the Development of a Candidate or the Commercialization of a Product Agreement at least [*****[ * ] days prior to its their intended presentation or submission for publication, publication and such submitting Party agrees, upon written request from the TSC within such [*****] day periodrequest, not to submit any such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****a reasonable period of time (resulting in a total of no more than [ * ] days from the date provision of such written request abstracts, manuscripts or presentation by one Party to seek appropriate the other for review until such Party’s submission of such abstracts, manuscripts or presentation for publication) to secure patent protection for any material in such publication or presentation which the JSC reasonably it believes is to be patentable. Once such abstracts, manuscripts Both Parties understand that a reasonable commercial strategy may require delay of publication of information or presentations have been reviewed by filing of patent applications. The Parties agree to review and decide whether to delay the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publicationpublication and filing of patent applications under certain circumstances. Each Neither Party also shall have the right to require that its publish or present Confidential Information that of the other Party which is disclosed in subject to Section 13.1. With respect to any such proposed publication or presentation be deleted prior made by AstraZeneca pursuant to such publication or presentation. In this Section 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Dynavax Technology in the Dynavax ISS, Collaboration ISS, CDs, Product and/or any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standardsCombination Product.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunderhereunder or prepublication of patentable data and content. It is agreed that both Parties may issue press releases only pursuant to Section 7.2. As long as ImmunoGen has not exercised a Co-Development Option to a Licensed Product, Biotest shall be entitled to publish details, data and/or results on the Research Program or the Development Program, e.g., in scientific articles or oral presentations, pursuant to this Section 7.3. Provided that ImmunoGen has exercised a Co-Development Option to a Licensed Product both Parties shall be entitled to publish in full range on the respective Licensed Product only pursuant to this Section 7.3. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Licensed Product, including, including but not limited to, studies or clinical trials carried out by such Party as part of the CollaborationCollaboration under this Agreement, without the prior review by and the approval of of, the JSC in accordance JDC, with Section 2.1respect to Development activities or, provided that ImmunoGen has exercised a Co-Development Option and a JMC has been established, the JMC, with respect to Commercialization activities. Each Party shall provide to the JSC JDC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, Program or the Development of a Candidate or the Commercialization of a Licensed Product at least [***] ([**] *]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC JDC within such [***] ([**] *]) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([**] *]) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC JDC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSCJDC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC JDC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research ProgramDevelopment, the Development of a Candidate or the manufacture, use and Commercialization of a Product, including, but not limited Licensed Product to the extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Lilly. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any material unpatented Technology disclosed in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Notwithstanding the foregoing or anything to the contrary herein, ImmunoGen acknowledges and agrees that Lilly may publish the registration of the initiation of and results of clinical trials that it conducts with respect to an Ab-May Product or Licensed Product on Lilly’s Clinical Trial Register to the extent required by Lilly policies and/or Applicable Laws and that such publication will not be a breach of the confidentiality obligations this Agreement.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication Genentech may publish or dissemination of present the final results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC Study (in accordance with this Section 2.1. Each Party shall provide 8.2), whether such results are positive or negative in any respect, such as with respect to the JSC the Combination or either Compound; provided that Genentech gives Corvus an opportunity to review and provide comments. Authorship of publications or presentations of any Study Data or Sample Data shall be determined in accordance with appropriate scientific and academic standards and customs. In the event that either Party (for purposes of this Section, the submitting “Publishing Party’s ”) wishes to publish or present any Study Data or Sample Data, the Publishing Party shall submit to the other Party (for purposes of this Section, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts or presentations (including information to be presented verballyand written descriptions of oral presentations) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation (or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period], not in the case of abstracts) prior to submit such abstract or manuscript the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to make such presentation until the other Publishing Party is given up to as soon as reasonably possible, but in any case within [***] (or [**] days from *], in the date case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such written Study Data or Sample Data, but shall give reasonable consideration to any request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSCReviewing Party; provided, however, at the request of the Reviewing Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Publishing Party also shall have the right to require that its Confidential Information that is disclosed in any (i) delete from such proposed publication or presentation be deleted prior Confidential Information of the Reviewing Party (including Sample Data owned solely or jointly by the Reviewing Party), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognizedfor [***], and co-authorship shall be determined in accordance with customary industry standards.to

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies Licensed Product to the extent such results refer to or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [***] ([**] *]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [***]-[***] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([**] *]) days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program to the Development of a Candidate or the Commercialization of a Product, including, but not limited extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Lilly. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research ProgramDevelopment, the Development of a Candidate or the manufacture, use and Commercialization of a Product, including, but not limited Licensed Product to the extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Lilly. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any material unpatented Technology disclosed in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.or

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication Sponsor may publish or dissemination of present the final results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC Sponsor’s Study(ies) (in accordance with this Section 2.1. Each Party shall provide 8.2), whether such results are positive or negative in any respect, such as with respect to the JSC the opportunity to review any Combination or either Compound. Authorship of the submitting Party’s proposed abstracts, manuscripts publications or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate any Study Data or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship Sample Data shall be determined in accordance with customary appropriate scientific and academic standards and customs. In the event that either Party (for purposes of this Section 8.2, the “Publishing Party”) wishes to publish or present any Study Data or Sample Data (whether final or partial), the Publishing Party shall submit to the other Party (for purposes of this Section 8.2, the “Reviewing Party”) all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral presentations) at least [*] (or [*] in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Reviewing Party shall review such submitted materials and respond to the Publishing Party as soon as reasonably possible, but in any case within [*] (or [*] in the case of abstracts) of receipt thereof. The Publishing Party will be permitted to publish or present such Study Data or Sample Data, but shall give reasonable consideration to any requests by the Reviewing Party; provided, however, at the request of the Reviewing Party, the Publishing Party shall (i) delete from such proposed publication or presentation Confidential Information of the Reviewing Party (including Sample Data owned solely or jointly by the Reviewing Party), provided that the Publishing Party shall have no obligation to delete any Study Data; and/or (ii) if such proposed publication or presentation contains patentable subject matter owned solely or jointly by the Reviewing Party, delay such proposed publication or presentation, for an additional [*] to permit the Reviewing Party to prepare and file a patent application. The Publishing Party shall comply with all applicable requirements regarding disclosure of industry standardssupport (financial or otherwise) in connection with any publications and presentations. For clarity, the provisions of this Section 8.2 only apply to publications or presentations of Study Data or Sample Data and do not apply to any other publications or presentations by a Party, including with respect to results from such Party’s development activities outside of the Study(ies). 8.3 Press Releases and Other Public Disclosures.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the research and Development activities hereunder. Except as required by Applicable LawsAccordingly, each during the Research Term neither Party agrees that it shall publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of the JSC and after the Research Term Dynavax shall not publish, present or otherwise disclose any material related to the Joint Research Programme or the Development or Commercialization of the CDs or the Product or any Combination Product(s) without the prior written consent of AstraZeneca. Each Party’s contribution to such results shall be duly recognised in such publications. For clarity, nothing in this Section 13.5 shall limit Dynavax’s right to publish or present, or permit to be published or presentedduring the Research Term, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, any studies or clinical trials carried out by such Party as part or on behalf of Dynavax prior to the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1Effective Date. Each Party shall agrees to provide to the JSC other Party the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verballyverbal presentations) which that relate to any Dynavax ISS or Collaboration ISS or Product or Combination Product studied under the Research Program, the Development of a Candidate or the Commercialization of a Product Agreement at least [*****[ * ] days prior to its their intended presentation or submission for publication, publication and such submitting Party agrees, upon written request from the TSC within such [*****] day periodrequest, not to submit any such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****a reasonable period of time (resulting in a total of no more than [ * ] days from the date provision of such written request abstracts, manuscripts or presentation by one Party to seek appropriate the other for review until [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. such Party’s submission of such abstracts, manuscripts or presentation for publication) to secure patent protection for any material in such publication or presentation which the JSC reasonably it believes is to be patentable. Once such abstracts, manuscripts Both Parties understand that a reasonable commercial strategy may require delay of publication of information or presentations have been reviewed by filing of patent applications. The Parties agree to review and decide whether to delay the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publicationpublication and filing of patent applications under certain circumstances. Each Neither Party also shall have the right to require that its publish or present Confidential Information that of the other Party which is disclosed in subject to Section 13.1. With respect to any such proposed publication or presentation be deleted prior made by AstraZeneca pursuant to such publication or presentation. In this Section 13.5, but without limiting anything set forth in Section 8.8.2 above, AstraZeneca shall give meaningful mention to Dynavax’s participation and contribution to the Collaboration and shall specifically mention the use of Dynavax Technology in the Dynavax ISS, Collaboration ISS, CDs, Product and/or any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standardsCombination Product.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research ProgramDevelopment, the Development of a Candidate or the manufacture, use and Commercialization of a Product, including, but not limited Licensed Product to the extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Lilly. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days (or such other period as the Parties may mutually agree) from the date of such written request to seek appropriate patent protection for any material unpatented Technology disclosed in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Notwithstanding the foregoing or anything to the contrary herein, ImmunoGen acknowledges and agrees that Lilly may publish the registration of the initiation of and results of clinical trials that it conducts with respect to an Ab-May Product or Licensed Product on Lilly’s Clinical Trial Register to the extent required by Lilly policies and/or Applicable Laws and that such publication will not be a breach of the confidentiality obligations this Agreement.

Publications and Presentations. The Parties acknowledge that scientific and medical publications and presentations will be made in a manner consistent with Third Party agreements in effect as of the Effective Date and industry standards for the development and Commercialization of drugs in the Field, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except The Parties will form a Publication Committee which will establish rules and procedures for scientific and medical publications and presentations, including publications and presentations relating to Biomarkers, Biomarker Information and Program Biomarker Technology. Such rules and procedures will include requirements for reasonable advance notice and expeditious review of proposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. The Publication Committee shall report to the JDC until such time as the JSC determines that the Publication Committee shall report to a different entity. Notwithstanding the foregoing, (i) except for disclosures permitted pursuant to Section 5.2, either Party, its employees or consultants wishing to make a publication shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days (or, in the case of consulting agreements, such shorter period (but not less than thirty (30) days) as required by Applicable Laws, each Party agrees that it shall not publish the consulting or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by other agreement with such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verballyconsultant) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until presentation, (ii) the other reviewing Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that a delay of up to ninety (90) days (or, in the case of consulting agreements, such shorter period (but not less than sixty (60) days) as required by the consulting or other agreement with such consultant) in publication or presentation in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship ownership shall be determined in accordance with customary industry standards. In negotiating consulting agreements, each Party shall use Commercially Reasonable Efforts to obtain the agreement of the consultant to the sixty (60) and ninety (90) day periods set forth in clauses (i) and (ii) above.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies Licensed Product to the extent such results refer to or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Program without the prior review by and the written approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, Program or the Development of a Candidate or the Commercialization of a Product Program at least [* (*****] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [* (*****] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (*****] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. Each Party (a) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, presentation at scientific conferences and meetings and (b) agrees that it shall not unreasonably withhold, condition or delay its consent to any request by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The BioNTech shall have the sole right, either itself or through its Affiliates or Sublicensees, to present or publish the results of, or scientific information relating to, any activities under this Agreement PROVIDED THAT prior to the [***] the Parties acknowledge that scientific will agree through the JSC on the content of any publications must be strictly monitored relating to prevent the [***] and/or [***]. Biotheus shall not make any adverse effect from premature publication or dissemination of results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish presentation relating to a Licensed Compound or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Licensed Product without the prior review by and the approval written consent of the JSC BioNTech. If, in accordance with the requirements and limitations of this Section 2.1. Each 10.3 (Publications and Presentations), a Party shall provide desires to publicly present or publish results or scientific information relating to a Licensed Compound or Licensed Product which publication contains the JSC the opportunity to review any Confidential Information of the submitting non-publishing Party’s , prior to doing so, the publishing Party will provide non-publishing Party with drafts of proposed abstracts, manuscripts or summaries of presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate that include such results or the Commercialization of a Product at least information. The non-publishing Party will respond no later than [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date after receipt of such written request to seek appropriate patent protection for any material in such proposed publication or presentation which the JSC reasonably believes is patentable. Once or such abstracts, manuscripts or presentations have been reviewed shorter period as may be agreed to by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publicationParties. Each The publishing Party also shall have the right to require that its Confidential Information that is disclosed in will delay any such proposed publication or presentation be deleted prior for a period up [***] days after the non-publishing Party receives such proposed publication or presentation to permit the non-publishing Party to make filings for patent protection and will otherwise remove its Confidential Information identified by the non-publishing Party in such publication or presentation. In any permitted publication or presentation by a Party, The Parties agree to acknowledge the other Party’s contribution shall be duly recognized, and co-authorship shall be determined contributions of one another in accordance with customary industry standardsstandard academic practice regarding authorship of scientific publication. Each Party agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party; provided that any listings or publications made pursuant to this Section 10.3 (Publications and Presentations). [***] will provide such assistance as [***] may reasonably require to obtain any consent or permission that may be required in order to publish data that originates from [***].

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program to the Development of a Candidate or the Commercialization of a Product, including, but not limited extent such results refer to, studies derive from or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Intellectual Property (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party; provided, that it shall not be deemed unreasonable for Lilly to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the planned publication or dissemination of such Covered Results by Lilly. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] days [***] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications must Jazz may publish or present, or permit to be strictly monitored to prevent any adverse effect from premature publication published or dissemination of presented, the design or results of the activities hereunderDevelopment, manufacture, use and Commercialization of the Licensed Product or Co-Development Product, if applicable (the “Covered Results”). Except ImmunoGen agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, Covered Results without the prior review by and the approval of Jazz, which approval shall not be unreasonably withheld, conditioned or delayed; provided, that it shall be deemed reasonable for Jazz to withhold its consent to any request by ImmunoGen to publish or present any Covered Results prior to the JSC in accordance with Section 2.1planned publication or dissemination of such Covered Results by Jazz. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts(a) abstracts and manuscripts for scientific journals or conferences that relate to the Covered Results at least [***] days prior to intended submission for publication, manuscripts or and (b) presentations at scientific conferences (including information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days Business Days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon presentation. Upon written request from the TSC a Party given within such [*****] day applicable review period, the other Party shall (i) not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for applications are filed to protect any material unpatented Technology disclosed in such publication or presentation which the JSC that such Party reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to may be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its patentable and (ii) remove any Confidential Information of such Party that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. Once such abstracts, manuscripts or presentations (or the information contained therein) have been reviewed and, if applicable, modified for publication or presentation pursuant to this Section 8.3, the same abstracts, manuscripts or presentations (and the information contained therein) do not have to be provided again by one Party to the other Party for review for a later submission for publication. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Development Program or the Development of a Candidate or the Commercialization of a ProductCollaboration Product or Collaboration Service, including, including but not limited to, studies or clinical trials carried out by such Party as part of the CollaborationCollaboration under this Agreement, without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, Development Program or the Development of a Candidate or the Commercialization of a Collaboration Product or Collaboration Service at least [*****] thirty (30) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party within such [*****] thirty (30) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] sixty (60) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC other Party reasonably believes is patentable. Once such abstracts, manuscripts or presentations have been reviewed by the JSCother Party, the same abstracts, manuscripts or presentations do not have to be provided again again, to the JSC either Party for review for a later submission for publication. Each Party also shall have the right to require that its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, recognized and co-authorship shall be determined in accordance with customary industry standards.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except Each Party agrees that, except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented, the results of the Research Program, Program or the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies Licensed Product to the extent such results refer to or clinical trials carried out by such Party as part of otherwise relate to the Collaboration, Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and the approval of the JSC in accordance with Section 2.1other Party. Each Party shall provide to the JSC other Party the opportunity to review any each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) which that relate to the Research Program, the Development of a Candidate or the Commercialization of a Product Covered Results at least [*****] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC other Party given within such [*****] day period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [*****] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation which the JSC that it reasonably believes is may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by the JSCeach Party, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards.the